A review of topiramate and phentermine: A combined therapeutic approach for obesity

Clinical Lipidology

Volumn 7, Issue 1, 2012, Pages 13-25

  Rubino, Domenica M ^a   Gadde, Kishore M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

combination drug therapy; obesity; pharmacotherapy; phentermine; teratogenicity; topiramate; weight loss

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; LORCASERIN; NORETHISTERONE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ALOPECIA; ANXIETY DISORDER; ATTENTION DISTURBANCE; BICARBONATE BLOOD LEVEL; BLURRED VISION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; CHEMISTRY; CLEFT PALATE; COGNITIVE DEFECT; CONCENTRATION LOSS; CONGENITAL MALFORMATION; CONSTIPATION; CONTROLLED DRUG RELEASE; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSGEUSIA; DYSPEPSIA; EYE DISEASE; EYE PAIN; FATIGUE; FECES INCONTINENCE; FLATULENCE; FOOD; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; HYPESTHESIA; IMMEDIATE DRUG RELEASE; INSOMNIA; IRRITABILITY; ISCHEMIC HEART DISEASE; LANGUAGE DISABILITY; LIFESTYLE MODIFICATION; LIPID DIET; LIVER INJURY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MENTAL DISEASE; METABOLIC ACIDOSIS; MONOTHERAPY; MOOD CHANGE; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDE; TACHYCARDIA; TERATOGENICITY; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84856860599     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.65     Document Type: Review

References (34)

1. Olshanksy SJ, Passaro DJ, Hershow RC et al. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352(11), 1138-1145 (2005). (Pubitemid 40365358)
2. Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359(20), 2105-2120 (2008).
3. Fontaine KR, Tedden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 289(2), 187-193 (2003). (Pubitemid 36068706)
4. Haslam DW, James WPT. Obesity. Lancet 366(9492), 1197-1209 (2005). (Pubitemid 41393598)
5. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N. Engl. J. Med. 356(3), 213-215 (2007). (Pubitemid 46143224)
6. Wadden TA, West DS, Neiberg RH et al. Look AHEAD Research Group: one-year weight losses in the look AHEAD study: factors associated with success. Obesity 17(4), 713-722 (2009).
7. Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr. Opin. Endocrinol. Diabet. Obes. 16(5), 353-358 (2009).
8. Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci. Biobehav. Rev. 32(1), 20-39 (2008). (Pubitemid 350160955)
9. Halford JC, Boyland EF, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat. Rev. 6, 255-269 (2010).
10. Dayyeh BK, Kaplan LM. Medical therapy for obesity. Gastrointest. Endosc. Clin. N. Am. 21, 203-212 (2011).
11. Salem V, Bloom SR. Approaches to the pharmacological treatment of obesity Exp. Rev. Clin. Pharmacol. 3(1), 73-88 (2010).
12. Rucker D, Padwal R, Ki SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-ana lysis. BMJ 335 (7631), 1194-1199 (2007). (Pubitemid 350273303)
13. James WP, Caterson ID, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10), 905-917 (2010).
14. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am. J. Ther. 16(4), 354-364 (2009).
15. Witkamp RF. Current and future drug targets in weight management. Pharm. Res. 28(8), 1792-1818 (2011).
16. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J. Obes. doi:10.1155/2011/179674 (2011) (Epub ahead of print).
17. Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol. 68(6), 830-843 (2009).
18. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29(1), 49-60 (2006). (Pubitemid 43780346)
19. Verrotti A, Scaparrotta A, Agostinelli S, DiPillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 95(3), 189-199 (2011).
20. Schutt M, Brinkoff J, Drenckhan M, Lehnert H, Sommer C. Weight reducing and metabolic effects of topiramate in patients with migraine-an observational study Exp. Clin. Endocrinol. Diabet. 118, 449-452 (2010).
21. Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Effcacy and safety of topiramate on weight loss: a meta-ana lysis of randomized controlled trials. Obes. Rev. 12(5), E338-E347 (2011).
22. Tremblay A, Chaput JP, Berube-Parent S et al. The effect of topiramate on energy balance in obese men: a 6 month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur. J. Clin. 63(2), 123-134 (2007). (Pubitemid 46147053)
23. Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topriamate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341-1352 (2011).
24. Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int. J. Neuropsychopharm. doi:10.1017/S1461145711000460 (2011) (Epub ahead of print).
25. Leombrini P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr. Dis. Treat. 5, 385-392 (2009).
26. Bialer M, Doose DR, Murthy B et al. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43(12), 763-780 (2004). (Pubitemid 39382219)
27. Brownell KD. The LEARN Program for Weight Management. The Life Style Company, TX, USA (2000).
28. Allison DB, Gadde KM, Garvey WT et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity doi:10.1038/oby.2011.330 (2011) (Epub ahead of print).
29. Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefts with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase 3 extension study. Am. J. Clin. Nutr. doi:10.3845/ajcn.111.024927 (2011) (Epub ahead of print).
30. Hunt S, Russell WH, Smithson L et al. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology 71(4), 272-276 (2008).
31. Hernandez-Diaz S, Mittendorf R, Homes LB. Comparative safety of topiramate during pregnancy. Birth Defects Res. (Part A) 88, 408 (2010).
32. Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305(19), 1996-2002 (2011).
33. Pack A, Meador K, Bhattachuria A. Retrospective analysis of major congenital malformations (MCMs) and oral clefts (OC) associated with in utero topiramate exposure. Epilepsia 52(6), 262 (2011).
34. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacology for obesity. Obesity 19, 2351-2360 (2011).